Background: Malignant gliomas rank among the most lethal cancers. Gliomas display a striking cellular heterogeneity with a hierarchy of differentiation states. Recent studies support the existence of cancer stem cells in gliomas that are functionally defined by their capacity for extensive self-renewal and formation of secondary tumors that phenocopy the original tumors. As the c-Myc oncoprotein has recognized roles in normal stem cell biology, we hypothesized that c-Myc may contribute to cancer stem cell biology as these cells share characteristics with normal stem cells.
Introduction
The emerging cancer stem cell model suggests that tumors are organized in a hierarchy with a subpopulation of cancer stem cells responsible for tumor maintenance and progression. Cancer stem cells are highly tumorigenic and phenocopy the original tumors in rodent xenograft models. Depletion of the cancer stem cell population greatly impairs the potential to initiate xenograft tumor formation of the bulk tumors [1, 2] . The cancer stem cell population also contributes to solid tumor angiogenesis [3] , metastasis [4] , and resistance to chemotherapy and radiotherapy [3, 5, 6, 7, 8, 9] . While this model has been validated in a growing list of haematopoietic and solid tumors, the molecular signaling pathways orchestrating the biology of cancer stem cells remain to be elucidated.
The c-Myc oncoprotein has been extensively studied for its instrumental role in proliferation and growth of normal and neoplastic cells. Deregulated c-Myc is found in diverse human tumors and is often associated with advanced malignancy and poor prognosis [10] . As c-Myc has been recently recognized as an important regulator of stem cell biology, it may serve as a link connecting malignancy and ''stemness'' [11] . In either normal or transformed cells, c-Myc alone activates an embryonic stem cell-like transcriptional module, which strongly correlates with tumor metastasis and mortality [12] . Ectopic c-Myc expression in transformed human keratinocytes dramatically increases the cancer stem cell fraction and enhances tumorigenicity [12] . Introduction of c-Myc with other transcription factors (including Oct3/4, Sox2, and Klf4) generates induced pluripotent stem (iPS) cells from differentiated cells [13] . Excluding c-Myc from this combination without eliminating endogenous c-Myc expression, drastically reduces the efficiency of iPS cell production [13, 14, 15, 16] . While all of these data suggest a role for c-Myc in maintaining stem cells, other functions of c-Myc in regulating stem cell biology have also been described. Conditional knockout of c-Myc in mouse bone marrow does not prevent proliferation or self-renewal of haematopoietic stem cells [17] . It rather results in accumulation of haematopoietic stem cells in bone marrow, suggesting that c-Myc specifically controls the interaction between haematopoietic stem cells and their niches. Additionally, over-expression of c-Myc-estrogen receptor fusion protein in human epidermal stem cells drives differentiation rather than proliferation [18, 19] .
Because of the recognized functions of c-Myc in both normal stem cell biology and neural malignancy, we investigated the role of c-Myc in human glioma cancer stem cells. Gliomas are the most common primary intrinsic tumor type of the central nervous system. High grade gliomas (World Health Organization grades III and IV) are among the most lethal human malignancies [20] . In glioma, c-Myc expression correlates with the grade of malignancy [21] . Expression of c-Myc driven by the glial fibrillary acidic protein (GFAP)-promoter in developing mouse astroglia induces tumors that resemble human glioblastoma multiforme [22] . In this mouse model, the tumor mass contains fast dividing subpopulation that express c-Myc and relatively quiescent tumor cells that lack c-Myc expression [22] . We have now determined that the glioma cancer stem cells expressed higher levels of c-Myc relative to matched non-stem tumor cells and the activity of c-Myc is required for proliferation, growth, and survival of glioma cancer stem cells. Loss of c-Myc abolished xenograft formation by glioma cancer stem cells, underscoring a key role of c-Myc in glioma cancer stem cell maintenance.
Results

Glioma cancer stem cells express high levels of c-Myc
To investigate the biological functions of c-Myc in regulation of glioma cancer stem cells, we first determined expression of c-Myc in these cells. Short term cultures enriched or depleted for cancer stem cells were derived from human brain tumor specimens using CD133 selection and characterized as we have previously demonstrated [9] . Quantitative real-time PCR revealed that CD133+ glioma cells expressed higher c-Myc mRNA levels than matched CD1332 glioma cells ( Figure 1A ). The differential mRNA levels translated into higher levels of c-Myc protein in CD133+ glioma cells than matched CD1332 cells ( Figure 1B) . Consistent with prior reports [23, 24] , the cancer stem cell-enriched fractions also expressed high levels of Olig2, a marker of adult neural multipotent progenitors ( Figure 1B ). To directly measure the expression of c-Myc in human brain tumors, we further evaluated c-Myc expression by flow cytometry in both CD133+ and CD1332 fractions of glioma cells acutely isolated from human surgical biopsy specimens without in vitro culture ( Figure 1C ). Approximately half of the CD133+ cells were high in c-Myc expression, whereas nearly 90% CD1332 cells expressed low levels of c-Myc ( Figure 1D ). We further examined c-Myc expression in glioma cancer stem cells using sections generated from acutely frozen human glioma surgical specimens. Because co-staining with CD133 was not compatible with antigen retrieval method required for c-Myc staining, we costained c-Myc with another neural stem cell marker Nestin. Greater than 90% of Nestin positive glioma cells were also c-Myc positive ( Figure 1E ). These data suggest that c-Myc is highly expressed in glioma cancer stem cells. Figure 3 ). In contrast, CD1332 cells displayed a lower rate of proliferation with a smaller S phase population than matched CD133+ cells (Figure 3 and data not shown), and the cell cycle progression in CD1332 cells was not significantly altered by knockdown of c-Myc. Regulation of the cell cycle by c-Myc is commonly mediated through transcriptional regulation of the cyclins and the cyclin-dependent kinase inhibitors, including cyclins D 1 , D 2 , and E and p21 WAF1/CIP1 [26, 27] (http://www. myc-cancer-gene.org). Attenuating c-Myc expression specifically reduced cyclin D 1 protein levels, but not cyclins D 2 or E, in CD133+ cells ( Figure 2B ). Additionally, p21 WAF1/CIP1 protein levels were upregulated in cancer stem cells depleted of c-Myc, whereas p53 levels were only moderately altered ( Figure 2B . Previous reports demonstrated that brain tumor stem cells isolated from human surgical biopsy specimens were actively proliferative in vitro [28, 29] , but the numbers of matched CD1332 tumor cells barely increased after a week of culture. Our data that the relatively high expression of c-Myc in glioma cancer stem cells is essential for their cell cycle regulation suggest that the growth of these cells may also require c-Myc activity. As demonstrated by growth curve assays, the total number of control CD133+ cells increased roughly six or seven fold over five days, whereas CD133+ cells depleted of c-Myc did not increase or decreased in number ( Figure 4) . Conversely, growth of the CD1332 population was only moderately attenuated with c-Myc knockdown ( Figure 4 ). These results suggest that c-Myc preferentially contributes to sustained growth of tumor initiating cells. 
Loss of c-Myc induces apoptosis in glioma cancer stem cells
Loss of c-Myc impairs neurosphere formation by glioma cancer stem cells
Sharing certain key characteristics of normal stem cells, cancer stem cells are capable of self-renewal, which allows sustained maintenance of this subpopulation and expansion of the whole tumor. Serial neurosphere formation assay has been utilized as a surrogate of the self-renewal capacity of neural stem cells [34] , and was recently employed in the brain tumor stem cells [9, 28] . In primary neurosphere formation assays, approximately 15% of control CD133+ cells formed neurospheres, whereas very few spheres were formed by cells depleted of c-Myc ( Figure 6A ). Neurospheres developed in 100% of wells in the control group when plated at a density of 100 cells/well and in 80-85% wells when plated at 10 cells/well ( Figure 6B ). In contrast, neurospheres were formed by cells depleted of c-Myc expression in only 10% (shRNA-1) or 30% (shRNA-2) of wells when plated at a density of 100 cells/ well, while no spheres were found when these cells were plated at 10 cells/well. Of note, neurospheres formed by cells with reduced cMyc expression were markedly smaller than the spheres formed by the control cells ( Figure 6C ) and merely met the minimal criteria to be scored in our experiments. Lack of neurospheres formed by glioma cancer stem cells depleted of c-Myc suggests impaired selfrenewal. However, assessing secondary neurosphere formation was precluded because very few spheres were generated in the knockdown groups in the primary assay and the neurospheres had limited viability. These studies therefore could not definitely determine if c-Myc expression is required for self-renewal of glioma cancer stem cells. However, it is expected that self-renewal of glioma cancer stem cells is inhibited by knockdown of c-Myc, based on our observations that glioma cancer stem cells failed to proliferate and underwent apoptosis upon knockdown of c-Myc.
Knockdown of c-Myc inhibits the tumorigenic potential of glioma cancer stem cells
Based on the requirement of c-Myc activity for cell cycle progression, growth and survival, of CD133+ glioma cells in culture, we examined the role of c-Myc expression in their tumorigenic potential. CD133+ glioma cells were infected with non-targeting control lentivirus or lentivirus expressing c-Myc shRNA. Following puromycin selection, 5000 cells of each group were injected into the brains of nude mouse in quadruplicate. 100% of mice bearing control cells rapidly developed neurologic signs and displayed large tumors on histopathology composed of pleomorphic cells featuring high nuclear to cytoplasmic ratios, prominent nucleoli with minimal cytoplasm, brisk mitotic activity and central geographic necrosis, consistent with a high grade glial malignancy ( Figure 7) . In contrast, no mice injected with cells depleted of c-Myc expression developed signs and after 100 days demonstrated no evidence of neoplastic cells (Figure 7) . Thus, cMyc appears to be essential for cancer stem cells to form tumors.
Discussion
The cancer stem cell hypothesis has engendered significant controversy, but the presence of heterogeneity of tumor cells in some cancers is well recognized. Tumor cells that display stem celllike characteristics and initiate xenograft tumors have been purified from an increasing number of cancers, including leukemia [35, 36] , brain [28, 29] , breast [37] , colorectal [38, 39] , pancreatic [40] , and head and neck cancers [41] . These cancer stem cells are functionally defined through assays of self-renewal and serial xenotransplantation assays in rodent models. Experiments demonstrate that the tumorigenic potential of cancer stem cells is at least several magnitudes higher than the bulk tumors. For example, glioma cancer stem cells enriched by selection of the CD133 surface antigen form orthotopic xenograft tumors with 500 cells in athymic nude mice, whereas 2610 6 CD1332 cells cannot [9] . In line with the potent tumorigenicity of brain tumor stem cells, we demonstrated here that CD133+ glioma cancer stem cells highly expressed the c-Myc oncoprotein. FACS analysis demonstrated that at least half of CD133+ cells acutely dissociated from human surgical biopsy specimens had high levels of c-Myc, whereas the majority (.85%) of CD1332 cells were c-Myc-low ( Figure 1D ). Similar co-expression of c-Myc and a stem cell marker, Nestin, was identified directly on human surgical biopsy specimen sections ( Figure 1E) . Notably, glioma cancer stem cells expressing c-Myc shRNA still retained residual levels of c-Myc protein ( Figure 2B , lanes 5 and 6) that were higher than the c-Myc levels found in CD1332 cells expressing non-targeting shRNA ( Figure 2B, lane 1) . Nonetheless, the reduced levels of c-Myc were incapable of supporting proliferation, growth, survival, and tumorigenesis of glioma cancer stem cells. A recent mouse model of T-cell lymphoma using conditionally expressed c-Myc also suggest that certain threshold level of c-Myc is required to maintain the tumor phenotype [42] . Collectively, our results highlight a necessary requirement of high c-Myc expression in glioma cancer stem cells.
Cancer stem cells have been proposed as slowly cycling cells, like their somatic stem cell counterparts [43] . Rapid expansion of tumors is then dependent on the fast dividing progenitor cells. The slow cell cycle may provide cancer stem cells a protective mechanism against certain therapeutic approaches that target rapid proliferating cells. For example, in human acute myelogenous leukemia, the quiescent leukemia stem cells are resistant to chemo-drugs that dependent on cell cycle [44] . Nevertheless, characteristics of cancer stem cells may not be necessarily uniform across different cancer types, and the biology of cancer stem cells may change throughout different stages of tumor development. In brain tumors, Singh and co-workers first demonstrated that only the CD133+ cancer stem cell population proliferate in vitro when acutely isolated from human surgical biopsy specimens [28, 29] . These results were similar to the highly proliferative cancer stem cells that were characterized in a RASinduced zebrafish embryonal rhabdomyosarcoma [45] . In the present study, we determined that the CD133+ glioma cells contained a higher percentage of S phase cells and grew faster in vitro than matched CD1332 cells (Figures 3 and 4) . We also found that proliferation and growth of glioma cancer stem cells were severely impaired upon knockdown of c-Myc, but importantly, the cell cycle progression of CD1332 glioma cells were relatively insensitive to loss of c-Myc. The transcriptional programs regulated by c-Myc remain poorly defined and dependent on cell state [26, 46] , but include induction of cyclin D 1 [47] and repression of the p21 WAF1/CIP1 cyclindependent kinase inhibitor [48, 49] . Consistently, expression of cell cycle regulators downstream of c-Myc, including p21 WAF1/CIP1 and cyclin D 1 , was altered in glioma cancer stem cells following c-Myc knockdown, but not in the CD1332 cells. These data uncover a Apoptosis can be induced by aberrant expression of certain oncogenes, such as c-Myc and E2F1, which may act as a ''fail-safe'' mechanism to eradicate potential cellular transformation [33, 50] . Apoptosis induced by c-Myc can be mediated through activation of the ARF-MDM2-p53 pathway, or by activating death receptors, such as CD95/Fas [33] . However, deregulation of c-Myc is common in human tumors and is an indicator of poor prognosis because tumors are well equipped with various anti-apoptosis mechanisms which can neutralize the apoptotic pressure introduced by c-Myc. Tumorigenesis in c-Myc transgenic mouse models is accelerated if combined with other anti-apoptosis genetic alterations, such as overexpression of Bcl-2 [51] or Bmi1 [52] , or disrupting the ARF-MDM2-p53 pathway [53] . Further, it has been directly demonstrated that sustained c-Myc activity is required for tumor maintenance in a variety of conditional transgenic mouse models. These models show that inactivation of c-Myc almost inevitably results in tumor regression regardless of tumor type with concomitant growth inhibition, differentiation, and apoptosis (reviewed in [54] ). In some cases, such as osteosarcoma [55] and skin tumors [56] , brief inactivation of c-Myc is sufficient to induce sustained tumor regression. However, the dependence on c-Myc can be tumor-type specific. In certain conditional transgenic models, reactivation of cMyc after transient disruption restores tumor growth [57] [61, 62, 63] . These models may represent outcome of loss of c-Myc in more homogeneous cancer cell populations, particularly genetically engineered models driven by overexpression of c-Myc. Our study has important implications as targeting c-Myc has unique benefits specific to cellular compartments in models representing cellular heterogeneity. Although targeting c-Myc was sufficient to prevent tumor growth in our studies, the dichotomous effects of c-Myc inhibition that we have detected may support the need to simultaneously target the non-stem cell tumor populations to achieve clinical efficacy. Thus, c-Myc as a molecular target must be approached with sophistication as the majority of tumor cells may demonstrate limited therapeutic responses but a critical tumor population -the cancer stem cellsmay be inhibited or killed to improve overall tumor control and decrease resistance to other therapies. Taken together, our study suggests that the proliferation, growth, and survival of glioma cancer stem cells are critically dependent on c-Myc expression and that targeting c-Myc pathways may significantly improve brain tumor therapy. 
Materials and Methods
Cell isolation and culture
Primary glioma surgical biopsy specimens were obtained from patients undergoing resection for newly diagnosed or recurrent glioma in accordance with protocols approved by the Duke University Medical Center Institutional Review Board. Written consent to utilize excess tissue for research was obtained from each patient, and de-identified tissues were used for all studies. Cells were isolated from human glioma surgical specimens and cultured as previously described [3, 9] . Briefly, tumors were dissected, washed in Earle's balanced salt solution, digested with papain, titurated, and filtered. Red blood cells were lysed in diluted phosphate buffered saline solution (0.256). Glioma cells were then cultured overnight in stem cell media (neurobasal media supplemented with B27 and epidermal growth factor and basic fibroblast growth factor (Invitrogen, Carlsbad, CA) at 20 ng/ml) prior to cell sorting for recovery of cellular surface antigens. The CD1332 and CD133+ fractions were separated by magnetic sorting using the CD133 Microbead kit (Miltenyi Biotec, Auburn, CA). CD1332 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (Invitrogen), but were cultured in stem cell media at least 24 hours prior to experiments to control differences in cell media. T3359, T3832, T4302 and T4597 were originally derived from human glioma surgical biopsy specimens and were maintained as subcutaneous xenografts in athymic BALB/c nude mice.
Antibodies
The antibodies used were as follows: Mouse anti-c-Myc antibody (9E10), FITC-conjugated rabbit anti-c-Myc antibody (A14), mouse anti-cyclin D 1 antibody (DCS-6), rabbit anti-cyclin D 2 antibody (H-289), mouse anti-cyclin E antibody (13A3), mouse anti-p53 antibody (DO-1) were from Santa Cruz Biotechnology (Santa Cruz, CA); APC-conjugated mouse anti-CD133 antibody (AC133-1) was from Miltenyi; goat anti-Olig2 antibody was from R&D Systems (Minneapolis, MN); mouse anti-p21
antibody was from Cell signaling Technology (Danvers, MA); mouse anti-actin antibody was from Millipore (Billerica, MA).
Immunofluorescent staining
Freshly frozen human glioma surgical biopsy samples were processed and 10 micron sections were mounted on glass slides in accordance with the Duke University Medical Center Institutional Review Board. Prior to staining, the sections were fixed in 4% paraformaldehyde at room temperature for 10 minutes, boiled in 10 mM sodium citrate solution (pH = 6.0) for 10 minute, and were blocked in 10% normal goat serum (Sigma-Aldrich, St. Louis, MO) and 0.1% Triton X-100 for 30 minutes at room temperature. Sections were incubated with primary antibodies at 4uC overnight and secondary antibodies at room temperature for 45 minutes, and then were counterstained with Hoechst 33342 (Invitrogen). For fluorescence imaging, confocal z-stacks were taken by a 636 water immersion objective lens on a Leica SP-5 microscope using sequential scans (blue-red, green). The following antibodies were used: mouse anti-c-Myc (Santa Cruz, 1:50), rabbit anti-Nestin (Abcam, Cambridge, MA, 1:100); goat anti-mouse 
Lentivirus production
The lentiviral vectors directing expression of shRNA specific to c-Myc (TRCN0000039640 and TRCN0000039641) or a nontargeting shRNA (SHC002) (Sigma-Aldrich) were co-transfected with the packaging vectors psPAX2 and pCI-VSVG (Addgene, Cambridge, MA) into 293FT cells by lipofectamine 2000 (Invitrogen) to produce virus. Two days following transfection, viral supernatants were collected, filtered, and concentrated by ultracentrifugation at 100,000 g for 3 hours.
FACS analysis
Glioma cells isolated from surgical biopsy specimens were fixed in 4% paraformaldehyde, and permeablized in 0.1% Triton X-100 for 10 minutes. Cells were then washed twice in PBS and labeled with APC-conjugated CD133 antibody (AC133, 1:11) and FITC-conjugated c-Myc antibody (A14, 1:50) for 1 hour at room temperate. Cells were then washed once in PBS and sorted.
Real-time PCR
Total RNA was prepared using the RNeasy kit (Qiagen, Valencia, CA), and reverse transcribed into cDNA by iScript cDNA synthesis kit (BioRad, Hercules, CA). Real-time PCR was performed on an ABI 7900HT system using SYBR-Green Mastermix (SuperArray, Frederick, MD). PCR products were verified by melting curves and were also run on a 2% agarose gel to confirm the appropriate size. The threshold cycle (C T ) values for 
Growth Curve and Neurosphere formation assay
Both CD1332 and CD133+ glioma fractions of glioma cells were infected by the control lentivirus or lentivirus directing expression of c-Myc shRNA and were selected with 1 mg/ml puromycin for 2 days. 5000 CD1332 cells or 1000 CD133+ cells were plated in 96-well plate in triplicate. Cell number was measured for 5 consecutive days using the CellTiter-Glo assay kit (Promega, Madison, MI). Additionally, 100 or 10 CD133+ cells were seeded per well in 24-well tissue culture plates. Eight wells were plated for each group. Seven days after plating, neurospheres containing more than 20 cells were scored.
Intracranial xenograft formation assay 5000 T3359 CD133+ cells lentivirally infected and selected for expression of the puromycin marker were implanted into brains of athymic BALB/c nude mice under a Duke University Institutional Animal Care and Use Committee-approved protocol. Mice were maintained for 100 days or until development of neurologic signs. Brains of euthanized mice were collected, fixed in 4% paraformaldehyde, paraffin embedded, sectioned, and subjected to hematoxylin and eosin staining.
